Back to blog

AstraZeneca Changes U.S. Exchange: What Does It Mean for European Investors?

At the beginning of the week, shares of pharmaceutical giant AstraZeneca rose by 1.5%* on the London Stock Exchange. The reason? It was a reaction to the planned transfer of trading from Nasdaq via American Depositary Receipts directly to the New York Stock Exchange (NYSE). In response, investors in Europe began to wonder: “What would such a move mean for my portfolio?”

AstraZeneca Changes U.S. Exchange: What Does It Mean for European Investors?

Harmonization

Chairman Michel Demare emphasized in an official statement that the new harmonized listing model is primarily intended to support the company’s long-term strategy of sustainable growth and access to global investors. The statement further noted that AstraZeneca remains firmly anchored in the United Kingdom—with its headquarters, tax residency, and primary listings in London and Stockholm. It can therefore be said that the transfer within the United States does not mean an escape from London but rather the company’s effort to expand its international investor base.

azn_ln

Source: Trading Economics*

London Under Pressure

The moves of major companies, however, evoke a broader trend. In recent years, London has faced a significant outflow of prestigious names—Unilever moved its activities to Amsterdam, while Glencore and Ashtead are considering similar steps. This is why news of a possible departure of AstraZeneca from London was perceived with concern. Based on current information, however, these concerns have been partially alleviated, though it is also clear that competition between stock exchanges is tougher than ever.

Political Dimension

The traditional political pressure from the U.S. is also not negligible. President Donald Trump repeatedly warned pharmaceutical companies that if they do not increase investment and production in the United States, they could face high tariffs. The move to list on the NYSE can therefore also be seen as a diplomatic gesture—a way to stay closer to U.S. investors and regulators without the company losing its European identity.

In addition, at the beginning of September the company decided to cancel its planned £200 million expansion of its research center in Cambridge, which at the same time signals that even in the United Kingdom the business environment is not without problems.

What Comes Next?

From a European investor’s perspective, AstraZeneca’s move to the NYSE is primarily about practical consequences. Expanding access to U.S. capital can support the company’s long-term growth, which may also be reflected in the performance of its shares on the London Stock Exchange. At the same time, however, this step is a reminder that London is no longer an automatic center for global companies, and the competitive pressure from the U.S. and the EU will continue to increase over time.[1]

*Past performance is not a guarantee of future results.

[1] Forward-looking statements represent assumptions and current expectations, which may not be accurate, or are based on the current economic environment, which may change. These statements do not guarantee future performance. By their nature, forward-looking statements involve risk and uncertainty, as they relate to future events and circumstances that cannot be predicted, and actual developments and results may differ materially from those expressed or implied in any forward-looking statements.

Disclaimer! This marketing material is not and must not be understood as investment advice. Past performance is not a guarantee of future results. Investing in foreign currency may affect returns due to fluctuations. All securities transactions may result in both profits and losses. Forward-looking statements represent assumptions and current expectations, which may not be accurate, or are based on the current economic environment, which may change. These statements do not guarantee future performance. CAPITAL MARKETS, o.c.p., a.s. is an entity regulated by the National Bank of Slovakia.

Sources:

https://www.investing.com/news/stock-market-news/astrazeneca-to-list-directly-on-nyse-while-keeping-uk-listing-shares-up-4259703
https://www.theguardian.com/business/2025/sep/29/astrazeneca-plans-new-york-stock-exchange-listing-but-isnt-quitting-london

Read more

Credo Technology: A Often Overlooked but Essential Link in the AI Revolution

Credo Technology: A Often Overlooked but Essential Link in the AI Revolution

While investors mainly focus on Nvidia, AMD, or OpenAI as the leading faces of artificial intelligence, behind this revolution operates a company without which no supercomputer or data center could function – Credo Technology. This firm from California’s Silicon Valley has gradually become one of the most important links in the AI infrastructure chain and, within two years, transformed from an unknown player into a stock market darling, rising toward its all-time high by more than 800%.*

TSMC: The Largest Chipmaker Once Again Confirms Its Dominance

TSMC: The Largest Chipmaker Once Again Confirms Its Dominance

Taiwanese semiconductor manufacturer, TSMC, has once again proved with its latest quarterly results why it is considered number 1 in its segment. In Q3, the company beat analysts' expectations of the London Stock Exchange Group (LSEG) on almost all key indicators. Revenue reached TWD 989.9 billion (approximately $33.1 billion), up 30% year-over-year, with net profit up 39%.

Tesla Exceeds Delivery Expectations: What’s Behind It?

Tesla Exceeds Delivery Expectations: What’s Behind It?

Last week, Tesla released its electric vehicle delivery results for the third quarter of 2025, and the numbers surprised investors. The automaker managed to increase deliveries by 7% year-over-year to 497,099 vehicles, surpassing Wall Street expectations by more than 49,000 units. However, despite this, Tesla’s stock price fell by 5.11%* after the announcement, ultimately suggesting that the market is looking beyond the headline figure.

Notice to clients

Notice to clients

InvestingFox, a registered trademark of CAPITAL MARKETS, o.c.p., a.s., warns against unfair practices associated with the misuse of its brand. InvestingFox distances itself from any activities or projects of similar-sounding brands.